Evidence map›Paper›PMID 35173016›Full record

SynthesisNeurology2022

Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.

Ingrid Anne Lie, Merlin M Weeda, Rozemarijn M Mattiesing, Marijke A E Mol, Petra J W Pouwels, Frederik Barkhof, Øivind Torkildsen, Lars Bø, Kjell-Morten Myhr, Hugo Vrenken

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 3 countries.

Ingrid Anne LieFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-9948-2411
Merlin M WeedaFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Rozemarijn M MattiesingFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Marijke A E MolFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Petra J W PouwelsFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Frederik BarkhofFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.ORCID 0000-0003-3543-3706
Øivind TorkildsenFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Lars BøFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Kjell-Morten MyhrFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.
Hugo VrenkenFrom the Department of Radiology and Nuclear Medicine (I.A.L., M.M.W., R.M.M., P.J.W.P., F.B., H.V.), MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Location VUmc; Department of Clinical Medicine (I.A.L., Ø.T., L.B., K.-M.M.), University of Bergen, Norway; Medical Library (M.A.E.M.), Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering (F.B.), UCL London, UK; Neuro-SysMed, Department of Neurology (I.A.L., Ø.T., L.B., K.-M.M.), Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology (L.B.), Haukeland University Hospital, Bergen, Norway.ORCID 0000-0001-9106-1172
Haukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere is currently no consensus about the extent of gray matter (GM) atrophy that can be attributed to secondary changes after white matter (WM) lesions or the temporal and spatial relationships between the 2 phenomena. Elucidating this interplay will broaden the understanding of the combined inflammatory and neurodegenerative pathophysiology of multiple sclerosis (MS), and separating atrophic changes due to primary and secondary neurodegenerative mechanisms will then be pivotal to properly evaluate treatment effects, especially if these treatments target the different processes individually. To untangle these complex pathologic mechanisms, this systematic review provides an essential first step: an objective and comprehensive overview of the existing in vivo knowledge of the relationship between brain WM lesions and GM atrophy in patients diagnosed with MS. The overall aim was to clarify the extent to which WM lesions are associated with both global and regional GM atrophy and how this may differ in the different disease subtypes.

methodsWe searched MEDLINE (through PubMed) and Embase for reports containing direct associations between brain GM and WM lesion measures obtained by conventional MRI sequences in patients with clinically isolated syndrome and MS. No restriction was applied for publication date. The quality and risk of bias in included studies were evaluated with the Quality Assessment Tool for observational cohort and cross-sectional studies (NIH, Bethesda, MA). Qualitative and descriptive analyses were performed.

resultsA total of 90 articles were included. WM lesion volumes were related mostly to global, cortical and deep GM volumes, and those significant associations were almost without exception negative, indicating that higher WM lesion volumes were associated with lower GM volumes or lower cortical thicknesses. The most consistent relationship between WM lesions and GM atrophy was seen in early (relapsing) disease and less so in progressive MS. DISCUSSION: The findings suggest that GM neurodegeneration is mostly secondary to damage in the WM during early disease stages while becoming more detached and dominated by other, possibly primary neurodegenerative disease mechanisms in progressive MS.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveNeurodegenerative DiseasesWhite MatterAtrophyBrainCross-Sectional StudiesGray MatterHumansMagnetic Resonance ImagingNeoplasm Recurrence, Local

Identifiers

PMID35173016
PMCPMC9038199
OpenAlexW4213065380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.